5-Fluorouracil: Forty-plus and still ticking. A review of its preclinical and clinical development

Investigational New Drugs

Volumn 18, Issue 4, 2000, Pages 299-313

  Grem, Jean L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antimetabolites; Pyrimidine analogs; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA; DRUG METABOLITE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; MESSENGER RNA; METHOTREXATE; MITOMYCIN C;

ADULT; AGED; ANIMAL MODEL; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; FEMALE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; IONIZING RADIATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NEUROTOXICITY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RAT; REVIEW;

ANIMAL; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS; FLUOROURACIL; HUMAN;

EID: 0033770342     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006416410198     Document Type: Review

References (129)

1. Studies on 2-acetylaminofluorene carcinogenesis: III. The utilization of uracil-2-C 14 by pre-neoplastic rat liver
2. Fluorinated pyrimidines. A new class of tumor inhibitory compounds
3. 5-Fluorinated pyrimidines
4. Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase
5. Mechanisms of interactions of thymidylate synthetase with 5-fluorodeoxyuridylate
6. Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5'-fluoro-2'-deoxyuridylate and methylene tetrachloride
7. Kinetics and thermodynamics of the interaction of 5-fluouro-2'-deoxyuridylate and thymidylate synthase
8. Cytotoxicity of 5-fluoro-2'-deoxyuridine
9. Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft
10. An overview of the current status and future directions of clinical trials of 5-fluorouracil and folinic acid
11. Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate
12. Interaction of deoxyuridine with fluorouracil and dipyridamole in a human colon cancer cell line
13. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxy-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole
14. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD 1694) and a non-polyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells
15. Preclinical and Phase I clinical studies with the non-classical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors
16. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion
17. Structure/function analysis of a dUTPase: Catalytic mechanism of a potential chemotherapeutic target
18. Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate
19. Mechanisms of excision of 5-fluorouracil by uracil DNA glycosylase in normal human cells
20. New mechanism of action of the cancer chemotherapeutic agent 5-fluorouracil in human cells
21. Deoxyribonucleoside triphosphate imbalance -fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death
22. Ratio of 2'-deoxyadenosine-5' triphosphate/thymidine-5'-triphosphate infuences the commitment of human colon carcinoma cells to thymineless death
23. Effect of interferon of 5-fluorouracil-induced perturbations in pools of deoxynucleotide triphosphates and DNA strand breaks
24. The effects of 5-fluompyrimidines on nascent DNA synthesis in Chinese hamster ovary cells monitored by pH-step alkaline and neutral elution
25. Modulation of fluorouracil cytotoxicity by interferons α and γ
26. A specialized form of ehromosomal DNA degradation induced by thymidylate stress in mouse FM3A cells
27. A specialized form of chromosomal DNA degradation induced by thymidylate stress in mouse FM3A cells
28. Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: Implications for mechanisms of resistance and cytotoxicity
29. Down-regulation of c-myc gene expression with induction of high molecular weight DNA fragments by fluorodeoxyuridine
30. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxyuridine in HT29 colon cancer cells
31. Etoposide-induced cytotoxicity in two human T-cell leukemic lines: Delayed loss of membrane permeability rather than DNA fragmentation as an indicator of programmed cell death
32. Methods in analysis of apoptosis and cell necrosis
33. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents
34. Bcl-2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways
35. Thymineless death in colon carcinoma cells is mediated via Fas signaling
36. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells
37. Regulation of thymidylate synthetase in mouse leukemia cells (L 12 10)
38. Regulation of thymidylate synthase enzyme synthesis in 5-fluorodeoxyuridine-resistant mouse fibroblasts during the transition from the resting to growing state
39. Levels of thymidylate synthetase during normal culture growth of L1210 cells
40. Interaction of interferon and 5-fluorouracil in the H630 human colon carcinoma cell line
41. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors
42. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase
43. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma
44. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer
45. Thymidylate synthase protein expression association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophagcal adenocarcinoma
46. Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture
47. The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro
48. 5-Fluorouracil inhibits dihydrofolate reductase precursor mRNA processing and/or nuclear mRNA stability in methotrexate-resistant KB cells
49. Acute effect of 5-fluorouracil on cytoplasmic and nuclear dihydrofolate reductase messenger RNA metabolism
50. Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil
51. An alternative molecular mechanism of action of 5-fluorouracil a potent anticancer drug
52. Effect of 5-fluorotiracil substitution on the self-splicing activity of Tetrahymena ribosomal RNA
53. Effects of 5-fluorouracil substitution on the RNA conformation and in vitro translation of thymidylate synthase messenger RNA
54. Effect of 5-fluoro and 5-bromouracil substitution on the translation of human thymidylate synthase mRNA
55. Catalytic mechanism and inhibition of tRNA Uracil-5-methyltransferase: Evidence for covalent catalysis
56. Interactions of transfer RNA pseudouridine synthases with RNAs substituted with fluorouracil
57. Enhanced cytotoxicity with interleukin-1α and 5-fluorouracil in HCT116 colon cancer cells
58. Inhibition by 5-fluorouracil of ERCCl and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line
59. 5-Fluorouracil suppresses nitric oxide biosynthesis in colon carcinoma cells
60. 5-Fluorouracil substitution alters pre-mRNA splicing in vitro
61. Ribonucleoprotein particle assembly and modification of U2 small nuclear RNA containing 5-fluorouridine
62. 5-Fluorouracil alters dihydrofolate reductase pre-mRNA splicing as determined by quantitative polymerase chain reaction
63. Incorporation of 5-fluorouracil into U2 and U6 snRNA inhibits mRNA precursor splicing
64. Inhibition of undine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence for the involvement of RNA perturbation
65. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
66. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival
67. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted infusion fluorouracil and weekly leucovorin
68. Novel mechanisms of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules
69. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells
70. Fluorouracil in colorectal cancer-a tale of two drugs: Implications for biochemical modulation
71. Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells
72. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells
73. Pooled analysis of phase II trials with low-dose 5-fluorouracil continuous infusion as a second line chemotherapy in advanced colorectal cancer
74. Activity of high dose 24 hour 5-fluorouracil infusion plus l-leucovorin in advanced colorectal cancer
75. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
76. Pharmacokinetics of fluorouracil in humans
77. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
78. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule
79. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma
80. Dose-intensification of 5-fluorouracil/high-dose leucovorin with granulocyte-macrophage colony stimulating factor in metastatic gastrointestinal cancer
81. Relationship between dihydropyrinlidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
82. Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer
83. A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma
84. Pharmacokineties of 5-fluorouracil administered orally by rapid intravenous and by slow infusion
85. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients
86. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients
87. Plasma pharmacokinetics or 5-FU given by continuous infusion with allopurinol
88. Phase I trial of 5-fluorouracil and dipyridamole administered by 72-hour concurrent continuous infusion
89. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with n-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma
90. Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routes
91. Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients
92. Altered plasma kinetics of 5-FU at high dosage in rat and man
93. Steady-state non-linear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients
94. A clinical pharmacological evaluation of hepatic arterial infusion of 5-fluoro-2'-deoxyuridine and 5-fluorouracil
95. The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases
96. Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893)
97. A double-blind comparison of intensive course 5-fluorouracil by oral vs intravenous route in the treatment of colorectal carcinoma
98. Fluorouracil therapy in patients with carcinoma of the large bowel: A pharmacokinetic comparison of various rates and routes of administration
99. Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients
100. Pharmacokinetics of 5-fluorouracil administered orally by rapid intravenous, and by slow infusion
101. Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man
102. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer
103. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridarnole
104. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer
105. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: Results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas
106. Circadian variation of 5-fluorouracil plasma levels during continuous infusion 5-FU and leucovorin in patients with hepatic or renal dysfunction
107. High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion
108. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells
109. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinie acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial
110. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer
111. Age and sex are independent predictors of 5-fluorouracil toxicity
112. Haematological and non-haematological toxieity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group
113. Adjuvant post-operative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of intergroup 0114
114. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors
115. Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells
116. Influence of sex and age on fluorouracil clearance
117. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
118. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy
119. Dihydropyrimidine dehydrogenase activity in cancer patients
120. Sex-orage-related differences were not detected in the activity of dihydropyrimidine dehydrogenase from rat liver
121. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
122. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer
123. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus
124. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial ( RTOG 85-01). Radiation Therapy Oncology Group
125. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
126. Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery
127. Epidermoid anal cancer: Results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and mitomycin C
128. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups
129. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer